Merck: Merck announces Keytruda as perioperative treatment with SOC adjuvant therapy significantly improved EFS compared to SOC alone in patients with resectable LAHNSCC

Merck, known as MSD outside of the United States and Canada, announced results from the phase 3 KEYNOTE─689 trial evaluating Keytruda (pembrolizumab), Merck's anti─PD─1 therapy, as a perioperative